Navigation Links
Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
Date:1/12/2009

Company In-licenses State-of-the-art CE-Marked Cobalt-Chromium Coronary Stent

Forms Alliance to Jointly Develop Drug Eluting Balloon Products

RALEIGH, N.C., Jan. 12 /PRNewswire/ -- Micell Technologies announced today that that the company entered into a strategic agreement with Maxcor Inc., the newly incorporated subsidiary of Opto Circuits (OCI) Ltd., by which Micell Technologies has obtained the rights to Maxcor's Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing Drug-Eluting Stents (DES) based on Micell's proprietary coating technology. The state-of-the-art stent and delivery system was developed and is marketed in Europe by EuroCor GmbH, a subsidiary of Opto Circuits. The companies also entered into an agreement to develop Drug Eluting Balloon (DEB) products for cardiovascular applications. The specific terms of the agreements have not been disclosed.

Micell's technology provides for a unique way for the delivery of drugs within bioabsorbable polymers. The company has developed a drug-polymer formulation that can precisely and consistently control drug elution and the duration of polymer exposure. As a result, Micell's coating has the potential to deliver a precise therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. The in-licensing of the Genius MAGIC Cobalt Chromium Coronary Stent System provides the optimal bare-metal stent product for the further development of the company's drug-polymer coating. In addition, the company believes that DEB will advance the treatment of many clinical conditions while minimizing risks or side-effects of these treatments.

Arthur J. Benvenuto, chairman and chief executive officer of Micell, said, "Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems. We are most impressed with OCI and the high quality and deliverability of their cardiovascular products. Indeed we look forward to working together to accelerate the development of new products that have the potential of improving patient care."

Vinod Ramnani, chairman and managing director, OCI, commented, "The science of medicating an interventional device is highly complex and requires exceptional clinical expertise and know-how. We are proud to begin working with Micell which has a strong intellectual property portfolio in this arena and which we hope will help give momentum to our jointly developed new products in new and regulated markets."

About Micell Technologies Inc

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. To learn more, please visit our Web site at www.micell.com.

About Opto Circuits (India) Ltd.

Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is a 100 percent EOU and a leading manufacturer of healthcare equipments in India. The product profile includes digital thermometers, sensors, probes, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired a 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003 and it now markets OCI's products in the US markets directly. OCI acquired EuroCor GmbH in 2006. EuroCor manufactures Cardiac Stents of various types, including Drug Eluting Coronary stents used in critical cardiac care. In April 2007, OCI ventured into new product segments - Urology, Gastroenterology, Gynecology and Orthopedics - after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). OCI completed the acquisition of US based Criticare Systems, Inc. in April 2008. Criticare designs, manufactures, and markets leading edge patient monitoring systems, vital signs monitors and gas benches for a wide range of hospitals and alternate health care environments throughout the world. Visit us at www.optoindia.com.

    Contact: Micell Technologies
    Arthur J. Benvenuto, Chairman & CEO
    (919) 313-2104


'/>"/>
SOURCE Micell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
2. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
3. Imugene and Merial Establish Strategic Alliance
4. Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Teams Strategic Gaming and Consulting Services
5. ADVENTRX Exploring Strategic Options
6. NeoStem Completes $500,000 Private Placement With Strategic Investor
7. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
8. SciQuest Announces Strategic Alliance with QIAGEN
9. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10. Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
11. Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):